他莫昔芬诱导非酒精性脂肪肝的机制研究进展

doi:10.12092/j.issn.1009-2501.2018.06.020

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (6): 715-720.doi: 10.12092/j.issn.1009-2501.2018.06.020

• 综述与讲座 • 上一篇

他莫昔芬诱导非酒精性脂肪肝的机制研究进展

陈曦¹，凌嘉伟¹，丁嘉欣¹，江振洲^1,3，张陆勇^1,2

¹中国药科大学江苏省新药筛选重点实验室，南京 210009，江苏；²广东药科大学药学院新药筛选与药效学评价中心，广州 510006，广东；³药物质量与安全预警教育部重点实验室（中国药科大学），南京 210009，江苏

收稿日期:2018-03-19 修回日期:2018-04-18 出版日期:2018-06-26 发布日期:2018-06-19
通讯作者: 张陆勇，男，教授，博导，研究方向：分子药理学，高通量高内涵药物筛选。 Tel：02583271023 Email: lyzhang@cpu.edu.cn
作者简介:陈曦，女，硕士研究生，研究方向：分子药理学。 Tel：18251982192 E-mail：chenxi199307@163.com
基金资助:
国家自然科学基金面上项目（81773827）；公益性行业科研专项（201507004-002）；国家重大新药创制专项（2015ZX09501004-002-004）；国家自然科学基金重大国际（地区）合作研究项目（81320108029）

Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen

CHEN Xi ¹, LING Jiawei¹, DING Jiaxin¹, JIANG Zhenzhou ^1,3, ZHANG Luyong ^1,2

¹ Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; ²Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China; ³Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, Jiangsu, China

Received:2018-03-19 Revised:2018-04-18 Online:2018-06-26 Published:2018-06-19

摘要/Abstract

摘要：

选择性雌激素受体拮抗剂他莫昔芬目前在临床上乳腺癌术后内分泌治疗的应用中最为广泛，然而，越来越多的证据显示他莫昔芬可大大提高乳腺癌患者非酒精性脂肪肝的发病风险。目前关于他莫昔芬造成肝脏脂毒性的研究并不详尽，其造成非酒精性脂肪肝的具体机制仍不明确，本文对他莫昔芬诱导非酒精性脂肪肝这一现象及其机制研究进展进行综述，为后续深入探索其机制及研发治疗药物提供参考。

关键词: 他莫昔芬, 辅助内分泌治疗, 非酒精性脂肪肝, 发病机制

Abstract:

Tamoxifen, a selective estrogen receptor antagonist, is most widely used for endocrine therapy for breast cancer. However, mounting evidence suggests that tamoxifen treatment can significantly improve the risk of nonalcoholic fatty liver disease (NAFLD) in breast cancer patients. At present, there is no enough research on hepatic lipotoxicity caused by tamoxifen, the exact mechanism of it is still unknown. In this paper, we reviewed the phenomenon and mechanism of tamoxifen induced nonalcoholic fatty liver disease, providing references for further mechanism research and therapeutic drugs development.

Key words: tamoxifen, endocrine therapy, nonalcoholic fatty liver disease, pathogenesis

中图分类号:

R575.5

陈曦，凌嘉伟，丁嘉欣，江振洲，张陆勇. 他莫昔芬诱导非酒精性脂肪肝的机制研究进展[J]. 中国临床药理学与治疗学, 2018, 23(6): 715-720.

CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong. Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.

参考文献

［1］Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review［J］. Ochsner J, 2017, 17(4): 405-411.
［2］替吉奥联合多西他赛治疗转移性乳腺癌的疗效及对血清HER2、VEGF及CA724水平的影响［J］. 空军医学杂志, 2017, 33(1): 33-35.
［3］Lin Y, Liu J, Zhang X, et al. A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer［J］. Cancer Sci, 2014, 105(9): 1182-1188.
［4］Gao FF, Lv JW, Wang Y, et al. Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice［J］. Biomed Rep, 2016, 4(1): 102-106.
［5］Yeh WL, Lin HY, Wu HM, et al. Combination treatment of tamoxifen with risperidone in breast cancer［J］. PLoS One, 2014, 9(6): e98805.
［6］Pan HJ, Chang HT, Lee CH. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients［J］. J Formos Med Assoc, 2016, 115(6): 411-417.
［7］Yan M, Wang J, Xuan Q, et al. The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer［J］. Clin Breast Cancer, 2017, 17(3): 195-203.
［8］张霞霞, 徐宏团, 徐有青. 非酒精性脂肪性肝病相关肝硬化的自然史与临床特点［J］. 临床肝胆病杂志, 2018, 34(1): 24-26.
［9］Yang YJ, Kim KM, An JH, et al. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients［J］. Breast, 2016, 28: 67-72.
［10］AkhondiMeybodi M, Mortazavy-Zadah MR, Hashemian Z, et al. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer［J］. Arab J Gastroenterol, 2011, 12(1): 34-36.
［11］闫永红, 党欢, 宋光辉, 等. 乳腺癌术后他莫昔芬治疗致脂肪肝［J］. 中国新药杂志, 2010, (21): 2016-2018.
［12］Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis［J］. Hepatology, 2010, 52(4): 1258-1265.
［13］Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver［J］. J Lipid Res, 2006, 47(10): 2223-2232.
［14］Lelliott CJ, Lopez M, Curtis RK, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis［J］. FASEB J, 2005, 19(9): 1108-1119.
［15］Le TT, Urasaki Y, Pizzorno G. Uridine prevents tamoxifen-induced liver lipid droplet accumulation［J］. BMC Pharmacol Toxicol, 2014, 15: 27.
［16］Gu W, Xu W, Sun X, et al. Anordrin eliminates tamoxifen side effects without changing its antitumor activity［J］. Sci Rep, 2017, 7: 43940.
［17］Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease［J］. J Gastroenterol, 2013, 48(4): 434-441.
［18］Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifeninduced hepatocyte steatosis in vitro［J］. Int J Mol Sci, 2014, 15(3): 4019-4030.
［19］赵斐, 谢萍, 姜佳丽, 等. 他莫昔芬体外促进HepG2细胞脂肪变性观察［J］. 实用肝脏病杂志, 2014, 16(1): 30-33.
［20］Larosche I, Letteron P, Fromenty B, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver［J］. J Pharmacol Exp Ther, 2007, 321(2): 526-535.
［21］Birzniece V, Barrett PHR, Ho KKY. Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development［J］. Eur J Endocrinol, 2017, 177(2): 137-143.
［22］Zhu L, Brown WC, Cai Q, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance［J］. Diabetes, 2013, 62(2): 424-434.
［23］Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat［J］. J Lipid Res, 2013, 54(2): 345-357.
［24］Han SI, Komatsu Y, Murayama A, et al. Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/liver X receptor pathway in mice［J］. Hepatology, 2014, 59(5): 1791-1802.
［25］Pedram A, Razandi M, O'mahony F, et al. Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling［J］. Sci Signal, 2013, 6(276): ra36.
［26］Wang X, Lu Y, Wang E, et al. Hepatic estrogen receptor alpha improves hepatosteatosis through upregulation of small heterodimer partner［J］. J Hepatol, 2015, 63(1): 183-190.
［27］Zhang ZC, Liu Y, Xiao LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice［J］. J Hepatol, 2015, 63(6): 1466-1475.
［28］Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis［J］. Toxicol Appl Pharmacol, 2015, 289(1): 40-47.
［29］Ohnishi T, Ogawa Y, Saibara T, et al. CYP17 polymorphism and tamoxifen-induced hepatic steatosis［J］. Hepatol Res, 2005, 33(2): 178-180.
［30］Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI［J］. PLoS One, 2018, 13(2): e0192663.
［31］Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD［J］? Clin Sci (Lond), 2017, 131(22): 2701-2704.
［32］Wang XC, Zhan XR, Li XY, et al. Identification and validation co-differentially expressed genes with NAFLD and insulin resistance［J］. Endocrine, 2015, 48(1): 143-151.
［33］赵雄, 范竹萍, 邱德凯, 等. 他莫昔芬对肝细胞胰岛素敏感性的影响［J］. 胃肠病学, 2010, 15(3): 139-142.
［34］Riggins RB, Schrecengost RS, Guerrero MS, et al. Pathways to tamoxifen resistance［J］. Cancer Lett, 2007, 256(1): 1-24.
［35］桑谊荃. 雌激素减少与腹型肥胖和胰岛素抵抗关系的研究进展［J］. 医学综述, 2013, 19(9): 1660-1662.
［36］Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal［J］. Oxid Med Cell Longev, 2014, 2014: 360438.
［37］Polimeni L, Del Ben M, Baratta F, et al. Oxidative stress: New insights on the association of nonalcoholic fatty liver disease and atherosclerosis［J］. World J Hepatol, 2015, 7(10): 1325-1336.
［38］Albukhari AA, Gashlan HM, El-Beshbishy HA, et al. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats［J］. Food Chem Toxicol, 2009, 47(7): 1689-1695.
［39］Suddek GM. Protective role of thymoquinone against liver damage induced by tamoxifen in female rats［J］. Can J Physiol Pharmacol, 2014, 92(8): 640-644.
［40］邹琪婧. 线粒体脂质过载与胰岛素抵抗［J］. 现代医药卫生, 2012, 28(6): 880-882.
［41］Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies［J］. Fundam Clin Pharmacol, 2008, 22(4): 335-353.
［42］Naven RT, Swiss R, Klug-Mcleod J, et al. The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation［J］. Toxicol Sci, 2013, 131(1): 271-278.
［43］郭瑶雪, 邓晔, 李春, 等. 异烟肼致线粒体损伤引起药物性肝损伤研究进展［J］. 中国临床药理学与治疗学, 2015, 20(3): 356-360.
［44］Theodossiou TA, Yannakopoulou K, Aggelidou C, et al. Tamoxifen subcellular localization; observation of cellspecific cytotoxicity enhancement by inhibition of mitochondrial ETC complexes I and III［J］. Photochem Photobiol, 2012, 88(4): 1016-1022.
［45］Ribeiro MP, Santos AE, Custodio JB. Mitochondria: the gateway for tamoxifen-induced liver injury［J］. Toxicology, 2014, 323: 10-18.
［46］Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis［J］. Free Radic Biol Med, 2012, 52(1): 59-69.

[1]	王朝义, 宋强, 熊鑫, 王梦远. 肉芽肿性小叶性乳腺炎诊疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 910-917.
[2]	张明康, 马彦荣, 靳永文, 周燕, 崔睿睿, 武新安. 药源性急性间质性肾炎的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 419-428.
[3]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[4]	黄会珍, 韩磊, 林晓冬, 陈磊. 胰腺炎发病机制相关信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 109-113.
[5]	张亮, 廖勇群, 夏秦川, 周诗侗, 李小丽. 铁死亡调控信号通路以及在相关疾病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(2): 227-234.
[6]	赵正卿, 李雁鹏, 向小霞, 庄建华, 赵忠新. 慢性失眠的发病机制与认知行为治疗[J]. 中国临床药理学与治疗学, 2021, 26(5): 482-486.
[7]	张晓丽, 刘毅 . 瞬时受体电位离子通道与银屑病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 469-473.
[8]	孙红, 侯佳林, 蔡加琴, 魏晓霞, 庄捷. SUMO E3连接酶介导雄激素受体的转录促进乳腺癌他莫昔芬耐药[J]. 中国临床药理学与治疗学, 2021, 26(3): 285-291.
[9]	金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.
[10]	吴敏，过怿赟，谢海棠. 乳腺癌患者体内他莫昔芬的群体药代动力学研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 418-423.
[11]	周红萍，杨兴鑫，庄让笑，邵益丹，席建军，廖莉，任白鹭，王萍萍，余舒莹，史婷婷. N-乙酰半胱氨酸活性炭缓释微囊对幼鼠非酒精性脂肪肝病miRNA的影响[J]. 中国临床药理学与治疗学, 2018, 23(3): 263-270.
[12]	赵巧云，范广民，阮正英，应香岚. PTEN和BID在宫颈癌组织中的表达及意义[J]. 中国临床药理学与治疗学, 2016, 21(11): 1246-1250.
[13]	唐若愚, 屈莺歌, 许洪涛, 阎澜, 颜天华, 姜远英, 曹永兵. 红景天苷防治急性高原病的作用及机制[J]. 中国临床药理学与治疗学, 2015, 20(7): 822-827.
[14]	王莹莹, 程光华, 濮之晨, 葛俊亮, 谢彦, 陈晓磊. CYP2D6^10和CYP2C19^2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 552-556.
[15]	娄晓亚, 孙红, 周宏灏. 表观遗传修饰-他莫昔芬耐药机制研究的新方向[J]. 中国临床药理学与治疗学, 2015, 20(4): 460-465.

他莫昔芬诱导非酒精性脂肪肝的机制研究进展

Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价